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Biologic therapies for rheumatologic diseases, which are targeted at molecules involved in the mechanisms of the
immune system, provide an alternative to the existing treatment methods of disease-modifying anti-rheumatic
drugs and other immunosuppressive medications. However, the current drawbacks of biologic therapies, including
the inconvenience of intravenous administration, the high costs of these drugs, and the adverse events associated
with them, prevent their wide use as first-line medications. This review provides an update of the recent literature
on the new biologic therapies available. The review concentrates on nine drugs: tocilizumab, rituximab,
ofatumumab, belimumab, epratuzumab, abatacept, golimumab, certolizumab, and sifalimumab, which are used as
therapies for rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, systemic sclerosis, or vasculitis.
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The use of biologic therapies as an adjunct to disease-
modifying anti-rheumatic drugs (DMARDs) for the
treatment of autoimmune and rheumatologic diseases is
rapidly expanding, owing to the good efficacy and safety
profiles of these drugs, and the better understanding of
the initial targets of altered immune regulation and
activity in various diseases. Targeted therapies such as
these are often well tolerated by patients. However, the
inconvenience of intravenous (IV) administration, as well
as the high costs and adverse events (AEs) associated with
these drugs prevent their wide use as first-line medica-
tions. The major targets of most biologic therapies are
cytokines, B cells, and co-stimulation molecules. Anti-
cytokines include anti-tumor necrosis factor (TNF)-α,
anti-interleukin (IL)-1, and anti-IL-6 molecules. B-cell
depletion includes use of anti-CD20 antibodies and B cell
receptor (BCR) modulation by the B-lymphocyte stimula-
tor (BLyS). Although some of the biologic therapies have
been found to be useful in more than one disease, others
are specific for a single disease. Research is ongoing to
identify other molecular targets.* Correspondence: goddard@wolfson.health.gov.il
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reproduction in any medium, provided the orIn this review, we provide an update on some of the
new agents that have become available in the past 5 years
for clinical treatment of rheumatoid arthritis (RA),
spondyloarthropathy, systemic sclerosis (SyS), systemic
lupus erythematosus (SLE), and vasculitis.
Methods
We performed a thorough literature review of all papers in
English published in PubMed during the period 1 January
2007 to 30 April 2012. We matched the terms: ‘rheumatoid
arthritis’, ‘spondyloarthropathy’, ‘systemic sclerosis’, ‘systemic
lupus erythematosus’, and ‘vasculitis’ with the terms ‘bio-
logics’, ‘tocilizumab’, ‘rituximab’, ‘ofatumumab’, ‘belimumab’,
‘epratuzumab’, ‘abatacept’, ‘golimumab’, ‘certolizumab’, and
‘sifalimumab’. Reports of randomized controlled trials
(RCTs) and case series were included. Case reports and
any reports of biologic therapies that are not yet available
for clinical use were excluded. We excluded articles that
were in a language other than English.
Screening for biologic treatment
Over a decade has passed since the introduction of biologic
therapies for autoimmune diseases. Currently, screening is
routine practice prior to administration of these drugs,
and is often performed during the initial visits to the
outpatient clinic to prevent unnecessary waits for thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of evaluation for previous or current tuberculosis (TB)
infection (based on history, purified protein derivative
(PPD) test, chest radiography), serological evidence of
hepatitis B and C, history of malignancies or neurological
disease. Based on the screening results, the physician will
assess which biologic treatment is recommended or if prior
treatment is warranted before the initiation of the biologic
therapy. The choice of biologic agent for rheumatologic
diseases is then tailored to the patient's needs and lifestyle.Tocilizumab
Mechanism
Tocilizumab (TCZ; trade names Actemra, Roactemra) is a
recombinant monoclonal IgG1 anti-human IL-6 receptor
(IL-6R) antibody (Table 1) [1]. IL-6 binds to either
membrane-bound or soluble IL-6R, and this complex in
turn binds to the 130 gp signal transducer. This process
enhances the inflammatory cascade, inducing angiogenesis
and amplifying the activity of adhesion molecules and the
activation of osteoclasts [2,3]. IL-6 is also responsible
for activating both T and B helper cells, and is involved
in B-cell differentiation, thus by blocking IL-6, the
inflammatory response is decreased [2].
In patients with RA, a high level of IL-6 is present in the
blood and in the synovium of involved joints. In an animalTable 1 Update on biologic therapy in autoimmune diseases
Drug (trade name) Mechanism of action
Tocilizumab (Actemra) Recombinant monoclonal IgG1 a
6-receptor antibody [1]
Rituximab (Rituxan) Chimeric human monoclonal ant
CD20 protein [12]
Ofatumumab (Arzerra) Fully human monoclonal antibod
membrane proximal epitope on
Belimumab (Benlysta) Human monoclonal immunoglob
which binds to and inhibits the s
BLyS protein [27,28]
Epratuzumab (Lymphocide) IgG1 monoclonal antibody direct
molecule [29,30]
Abatacept (Orencia) CTLA-4 IgG1 binding to CD80/86
cells inhibiting the co-stimulation
cells [32]
Golimumab (Simponi) IgG1 monoclonal antibody, actin
soluble and membrane-bound [3
Certolizumab (Cimzia) Pegylated humanized antibody F
TNF-α monoclonal antibody [42]
Sifalimumab An anti-IFN-α monoclonal antibo
Intravenous immunoglobulin Pool of immunoglobulins from h
mechanisms involved [48,49]
Anakinra (Kineret), canakinumab (Ilaris),
rilonocept (Arcalyst)
All three are interleukin-1 blocker
1Approved by the US Food and Drugs Administration. Abbreviations: AS, ankylosing
periodic syndrome; CTLA, cytotoxic T lymphocyte-associated; JIA, juvenile idiopathic
arthritis; SLE, systemic lupus erythematosus; TNF, tumor necrosis factor; Wegener’s gstudy, injecting TCZ into the inflamed joints reduced the
swelling and the inflammatory response [2,4].
Indications and dosage
TCZ is indicated for the treatment of RA following an
inadequate response or treatment failure with DMARDs
or TNF alpha antagonists (anti-TNF alpha drugs). It is
also indicated as first-line therapy for patients with
severe systemic juvenile idiopathic arthritis (SJIA) and
for Castleman's disease (Table 1).
The recommended dose of TCZ is 8 mg/kg every
4 weeks. The drug was approved for RA in January 2010
in the USA, but the US recommendations are for a
starting dose of 4 mg/kg once every 4 weeks, followed
by an increase to 8 mg/kg depending on clinical
response [5,6]. The route of administration is IV, with
the dose of 4 to 8 mg/kg IV administered as a single
infusion every 4 weeks for RA and 12 mg/kg or 8 mg/kg
IV (depending on body weight) for SJIA [6]. Within an
RA population, in Disease Activity Score(DAS) remission
rate was 55.3% for patients treated for 5 years on mono-
therapy [7].
Efficacy
A meta-analysis examined published articles on double-
blind, randomized, placebo-controlled trials that indirectly
compared TCZ with one or more of the followingIndications
nti-human interleukin RA after treatment failure with anti-TNF,1
SJIA1 [5-7]
ibody against the RA,1 WG, MPA. Off-label use: ITP, refractory
pemphigus vulgaris [13-23]
y directed against
the CD20 molecule [25]
RA,1 [24,25]
ulin IgG1 gamma,
oluble form of the
SLE1 [26,27]
ed against the CD22 SLE, Sjögren’s syndrome [28-30]
on antigen-presenting
of CD28 on the T
RA,1 JIA,1 SLE – discoid, serositis and arthritis
manifestations [31-35]
g on TNF-α, both
7]
RA,1 PsA,1 AS1 [36-40]
ab0 fragment of the RA1 [41,42]
dy [44] Phase III trial [43,44]
ealthy individuals. Many SLE, systemic sclerosis, vasculitis [49,50]
s RA, CAPS [45-47]
spondylitis; BLyS, B-lymphocyte stimulator; CAPS, cryopyrin-associated
arthritis; MPA, microscopic polyangiitis; PsA, psoriatic arthritis; RA, rheumatoid
ranulomatosis.
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blockers (etanercept, infliximab, and adalimumab), in pa-
tients with inadequate response to DMARDs and/or anti-
TNF-alpha blockers. TCZ was non-inferior compared
with the other biologic therapies according to the Ameri-
can College of Rheumatology (ACR) criteria for a 20%
(ACR20) or 50% (ACR50) improvement, and was superior
for a 70% improvement (ACR70) [8]. Furthermore, the
response to TCZ occurred early, soon after the first
infusion [1].
Monotherapy with TCZ for 52 weeks resulted in
significantly reduced radiographic change (total Sharp
score) compared with DMARDs [2]. In a 24-week study
comparing TCZ and methotrexate (MTX), TCZ was
found to be non-inferior to MTX in the first week and
superior to MTX in the second week in the intention-to
-treat group, as measured by ACR20 [3]. Several other
studies comparing monotherapy of MTX with that of
TCZ have also shown superiority of TCZ [3,9]. In a
study of 1,196 patients with RA who responded partially
to MTX, treatment with TCZ led to suppression in
radiographic progression and improvement in physical
function [9]. Other studies reported response to TCZ in
patients with RA who failed to respond to anti-TNF
-alpha blockers [9].
Adverse effects and safety
Favorable safety results for TCZ were reported for both
short-term and long-term treatment of moderate to
severe RA. In one meta-analysis, TCZ was well tolerated
for more than 2.4 years of treatment, and the AEs were
less severe compared with other biologic therapies [8].
In a 24-week study of 286 patients with RA, 66.1% expe-
rienced AEs related to the drug, which were mild to
moderate and transient. A small number of patients
experienced serious AEs, which were predominantly
infections [1].
In a study integrating the three phases of TCZ safety,
the AEs were similar to the other treatment groups
(DMARDs or anti-TNF-alpha). The most common AEs
were infections, mostly of the upper respiratory tract
(URTI) and gastrointestinal (GI) tract [10]. More severe
AEs included cardiac events, serious infections, solid-
organ malignancies, non-melanoma skin tumors, and
hematological disturbances [10]. Higher rates of serious
infections were related to previous anti-TNF-alpha
treatment. The most common infections were pneumo-
nia, gastroenteritis, and urinary-tract infections [10].
Some patients were diagnosed with TB despite being
screened before treatment in accordance with the guide-
lines. Higher doses of TCZ (8 mg/kg) were associated
with higher risks for infection, but rates were still similar
to those encountered with DMARDs or anti-TNF-alpha
blockers [10]. GI perforation occurred in 16 patients(predominantly women) exposed to TCZ in the phase III
trials, with 11 of them developing diverticuli [10]. Some
patients developed a significant increase in liver-function
tests, indicating liver dysfunction; a dose reduction was
sufficient for the continuation of the study. Only 2.3% of
TCZ-exposed patients had to discontinue treatment
because of liver abnormalities [10]. There was a reduction
in neutrophil count in patients receiving TCZ, which sta-
bilized after 2 weeks of therapy. Some patients developed
grade 4 neutropenia, but the neutrophil count normalized
after discontinuation of therapy [10].
In other studies of monotherapy with TCZ, the AEs
reported were nasopharyngitis, GI symptoms, and infec-
tions. There was no difference in the incidence of AEs
with TCZ compared with anti- TNF-alpha blockers [3].
TCZ was associated with increases in cholesterol levels
and in the ratios of low-density lipoprotein (LDL) to
high-density lipoprotein (HDL) cholesterol, and of total
to HDL cholesterol [11].
In conclusion, TCZ is beneficial and safe for treatment
of RA in cases of non-response to anti-TNF-alpha therapy
or when anti-TNF-alpha therapy is contraindicated.
Rituximab
Mechanism
Rituximab (trade names Rituxan, Mabthera) is a chimeric
human monoclonal antibody against the CD20 protein
found on naive, mature, and memory B cells. Rituximab
depletes the B-cell population via apoptosis, cellular
cytotoxicity, and complement activation. In a number of
studies measuring markers for immature B cells, memory
B cells, and pre-B cell colony-enhancing factor (visfatin),
B-cell depletion occures after treatment with rituximab
[12]. In addition, rituximab affects the interferon (IFN) I
response genes. In patients with RA responding to ri-
tuximab treatment, expression of IFN response genes
(RSAD2,IFNI44L, HERC5, LY6E, Mx1) increased, whereas
the non-responding patients had limited or no IFN gene-
expression activity (Table 1) [12].
Indications and dosage
For autoimmune diseases, the only indication for which
rituximab is approved by the Food and Drugs Adminis-
tration (FDA) is active RA unresponsive to DMARDs
and anti-TNF-alpha agents. Rituximab is beneficial for
other off-label indications in patients with autoimmune
disease (such as SLE) and Castleman's disease (Table 1).
The most popular protocol for RA is IV infusion of
1000 mg/m2 on days 1 and 15 in combination with MTX.
Subsequent courses may be administered every 24 weeks
(based on clinical evaluation), and if necessary, may be
repeated, but no sooner than every 16 weeks. For patients
with RA, pre-medication with IV methylprednisolone
100 mg (or equivalent) is recommended, 30 minutes before
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polyangiitis (GP) (previously Wegener's granulomatosis),
the protocol is different: IV infusion with 375 mg/m2
once weekly for four doses (in combination with IV
methylprednisolone for 1 to 3 days followed by daily
prednisone). The protocol for microscopic polyangiitis
(MPA) is similar to that of GP [14].
Rituximab was evaluated for chronic immune throm-
bocytopenic purpura (ITP) in a multi-center phase II
study of 60 patients, who received an IV infusion of
375 mg/m2 once weekly for 4 doses; 40% of patients
achieved a steady platelet level [15]. A few studies also
suggested that low-dose treatment with 100 mg/m2,
either alone or in combination with steroids would
suffice and result in fewer AEs; however, further data on
this dose are lacking [15].
For refractory pemphigus vulgaris (PV), the recom-
mended treatment is IV infusion of 375 mg/m2 rituximab
once weekly in weeks 1, 2, and 3 of a 4-week cycle, which
is repeated for one additional cycle, followed by one dose
per month for 4 months (total of ten doses in 6 months)
[16]. The initial infusion should be started at 50 mg/hour,
and if there is no reaction, the rate should be increased by
50 mg every 30 minutes (100 mg/hour).
Efficacy
Several studies suggest that rituximab may be beneficial
for the treatment of SyS [17]. In a study of eight patients
with SyS, the B-cell infiltrate was depleted in the skin
after rituximab infusion, signifying that the drug might
be a possible therapy for skin fibrosis [17]. Another
study of 15 patients with SyS also showed histological
improvement in the skin after rituximab therapy [17].
In a study of 257 patients with SLE treated with rituxi-
mab and prednisone, disease activity was not signifi-
cantly improved compared with placebo. However, in a
subgroup analysis of African American and Hispanic
patients, there was a significant benefit for rituximab ther-
apy. Furthermore, in open trials for long-term treatment,
rituximab was found to be superior [18]. The lack of
efficacy in the overall trial could be associated with the
clinical set-up of the trial, inclusion of too many subsets,
or non-stratification of patients positive or negative for
anti-double-stranded DNA antibodies [19].
A case series indicated that rituximab might be benefi-
cial in hemolytic anemia, thrombocytopenia, and arthritis-
related SLE [20].
In a study of 646 patients with RA who had treatment
failure with anti-TNF-alpha blockers, follow-up at 6 months
after therapy with rituximab resulted in a good clinical
response and even remission of the disease [21].
In the SUNRISE (Study of Retreatment with Rituximab
in Patients with Rheumatoid Arthritis Receiving Back-
ground Methotrexate) trial, 559 patients with RA withinadequate response to one or more TNF-alpha inhibi-
tors were given two treatment cycles of rituximab to
assess the efficacy and safety profile of the drug. Of the
total 559 patients in the study, 475 patients received the
second cycle of therapy, with a significant response com-
pared with the placebo group, as measured by the
ACR20 [13].
In a study of 42 patients with severe PV, rituximab was
administered as monotherapy, inducing remission in 36
patients for periods of 8 to 64 months. In those patients
requiring an additional dose, the safety profile remained
good [16].
Adverse effects and safety
One of the AEs associated with rituximab is an infusion
reaction, characterized by fever, chills, rash, swelling (of
hands, feet, and face), bronchospasm, and hypotension.
In most cases, the reaction is immediate (30 minutes to
2 hours), usually during the first infusion, but is less
severe with subsequent infusions. Pretreatment with
acetaminophen and an anti-histamine is recommended
to prevent this infusion reaction. If the infusion reaction
occurs, the infusion rate should be decreased or
discontinued. Additional treatment with steroids may also
be warranted. Rituximab treatment requires monitoring of
several AEs, including infections, TB, and lymphoma [22].
It is contraindicated in the case of pregnancy and
breastfeeding, active infections, live vaccination, severe con-
gestive heart failure, a history of demyelinating disease, and
a 5-year history of non-lymphoproliferative cancer [23].
In a meta-analysis assessing the safety of rituximab,
including long-term therapy, 123 of 2,578 patients with
RA withdrew because of malignancy, infection, a severe
infusion reaction, or cardiac event [22]. Most AEs oc-
curred during the first course of therapy. The incidence
of malignancies was not increased in patients with RA
treated with rituximab [22].
Rituximab causes a decrease in gammaglobulin con-
centrations, depending on the cumulative dose; however,
this does not seem to lead to a higher risk for severe
infection [23]. A few cases of progressive multifocal
leukoencephalopathy (PML) were reported in some pa-
tients after rituximab therapy [22].
Ofatumumab
Mechanism
Ofatumumab (trade name Arzerra) is a fully human
monoclonal antibody directed against the membrane
proximal epitope on the CD20 molecule (Table 1) [24-25].
Indications and dosage
Ofatumumab is indicated for the treatment of chronic
lymphocytic leukemia. Owing to its B-cell-suppressing ef-
fect, it is also used in the USA and Europe as an off-label
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apy (Table 1). In a combined phase I and II study, patients
received three escalating doses of ofatumumab (300, 700,
and 1000 mg), with each dose given as two separate IV
administrations with 2 weeks between them, over a period
of 24 weeks [25]. Prior to administration, all patients
in the high-dose groups received premedication with
acetaminophen, anti-histamine, and glucocorticoids.
The recommended protocol for maximum efficacy and
safety is IV administration of 700 mg over 4 hours with
appropriate premedication, repeated every 2 weeks [24,25].
Efficacy
Two studies reported efficacy of ofatumumab compared
with placebo or MTX in patients previously treated with
DMARDs or biologic therapies; all such therapies were
discontinued prior to study entry [24,25]. In one study,
comparing the efficacy of ofatumumab (three different
dose groups) with patients treated with placebo or MTX,
significantly higher rates of ACR20 were seen in the
ofatumumab groups compared with the placebo group. In
addition, the efficacy was dose-dependent, as assessed by
the ACR20 and the circulating B-cell population [24].
In another multi-center double-blind RCT of biologic
therapies in naive patients with RA, ofatumumab 700 mg
was compared with placebo, and a significantly higher rate
of improvement as measured by ACR20 was noted in the
ofatumumab group [25]. No significant differences were
noted between seronegative and seropositive patients in
this study [25].
Adverse effects and safety
In a study comparing the safety of ofatumumab (three
different dose groups), the main AEs were related to
infusion reaction, which was mild to moderate and oc-
curred mainly with the first and second administrations
[24]. However, after 24 weeks of treatment, a significant
number of AEs occurred in the highest-dose (1000 mg)
group [24]. No difference in infections was noted between
the different dosage groups and the placebo [24]. Other
AEs included rash, dyspnea, rhinitis, nausea, pruritus,
URT infections, headaches, fatigue, flushing, hypertension,
and diarrhea.
In another double-blind multi-center study, the most
common reactions were urticaria and rash on the day of
the first infusion. Most of the reactions were mild to
moderate, and severe AEs were infrequent [25]. No case
of PML was reported [25].
Belimumab
Mechanism
The BLyS protein is a member of the superfamily of
TNFs. It inhibits B cell apoptosis and stimulates the
differentiation of B cells into immunoglobulin-producingplasma cells. Belimumab (trade name (Benlysta) is a
human monoclonal immunoglobulin (IgG1γ), which
binds to and inhibits the soluble form of the BLyS
protein [26,27] (Table 1).
Indications and dosage
Belimumab is approved by the FDA for the treatment of
mild to moderate SLE, and is presently not indicated for
active LE nephritis or neuropsychiatric involvement
(Table 1) [26,27]. It is given by slow IV infusion over 1 hour
at a recommended dose of 10 mg/kg at 2-week intervals
for three cycles, then once every 4 weeks [26,27].
Efficacy
In a phase II trial, there was a significant effect of
belimumab after 52 weeks of treatment and a steroid-
sparing effect. However, no improvement in the SLE
responder index (SRI), which incorporates disease activity
scores to compile a single score, disease activity score was
significant in SLE patients with severe active disease [26].
In the phase III clinical trials assessed using the SRI, a
significant improvement was seen in both the 1 mg/kg
and the 10 mg/kg groups compared with the placebo
group [28]. Significant changes were also reported in
the SELENA-SLEDAI (Safety of Estrogens in Lupus
Erythematosus National Assessment–Systemic Lupus
Erythematosus Disease Activity Index) trial, with non-
inferiority of belimumab compared with placebo, as mea-
sured by the Physician’s Global Assessment (PGA) [26].
Adverse effects and safety
AEs associated with belimumab treatment include nausea,
diarrhea, headaches, and URT infections. Less common
side effects are fever, cystitis, leucopenia, infusion reaction,
and severe infections. Studies have shown that the number
of AEs associated with belimumab were similar to that in
the placebo group, and that the severity and number of
AEs did not increase in the high-dose (10 mg/kg) group
compared with the low-dose (1 mg/kg) group [26,27].
Epratuzumab
Mechanism
Epratuzumab is an IgG1 monoclonal antibody directed
against the CD22 molecule. CD22 is a B-cell-specific
transmembrane sialoglycoprotein that inhibits the B-cell
receptor complex, causing early apoptosis and thus
shortening the cell’s life span (Table 1) [28,29].
Indications and dosage
The therapeutic dose of epratuzumab is 360 mg/m2 IV
over 1 hour every 2 weeks for up to four cycles. It is
recommended that acetaminophen and anti-histamine
should be administered prior to infusion to minimize
infusion reaction [30]. Owing to its anti-CD22 targeting
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SLE and Sjögren’s syndrome (Table 1) [30].
Efficacy
Although epratuzumab has not received regulatory
approval for SLE and Sjogren's syndrome, several studies
have assessed the drug for these two conditions (excluding
patients who were previously treated with rituximab). In a
study measuring scores on the British Isles Lupus Assess-
ment Group (BILAG) scale during a follow-up of 6 months,
all patients had a decrease in disease activity of more than
50% [30]. In a larger study of 227 patients with moderate
to severe SLE, comparing doses of 600, 800, 2,400, or
3,600 mg epratuzumab with placebo for 12 weeks, all
epratuzumab groups had a significant response as mea-
sured by BILAG score [29]. In a different study of patients
with Sjögren’s syndrome, 67% of patients responded to
6 months of epratuzumab therapy, indicating regeneration
of glandular tissue [30].
Adverse effects and safety
In the phase II trial of 227 patients described above,
there was no significant difference in AEs between the
placebo group and any of the epratuzumab groups [30].
In the study of patients with SLE, most of the AEs were
minor, and included nausea, fatigue, general pain, and
infusion reaction [30]. Patients with Sjögren’s syndrome
had more severe AEs during the infusion, including




T cells play a major role in the pathogenesis of RA.
Co-activation of CD28 with the antigen-presenting cell
(APC) protein CD80/86 results in release of inflammatory
cytokines. Cytotoxic T lymphocyte-associated (CTLA)-4
is a protein with a high affinity to CD80/86, which inhibits
T-cell activation by blocking the CD28 binding. Abatacept
(trade name Orencia) is a CTLA-4 IgG1 that binds to
CD80/86 on APCs, inhibiting the co-stimulation of CD28
on T cells (Table 1) [31].
Indications and dosage
Abatacept is approved by the FDA for the treatment of RA
that is non-responsive to DMARDs and anti-TNF-alpha
blockers, and for JIA (Table 1). For RA treatment, the dose
is based on body weight, with a dose of approximately
10 mg/kg (patients weighing less than 60 kg receive
500 mg; those weighing 60 to 100 kg received 750 mg,
and those weighing more than 100 kg receive 1000 mg).
The initial IV dose can be repeated by additional doses
after 2 and 4 weeks, with further doses every 4 weeks after
that. Another treatment option after the initial IV dose isto administer a subcutaneous (SC) injection of 125 mg at
24 hours after the first infusion, repeated by weekly SC
injections of 125 mg [31,32].
For JIA, the route of administration is also IV, and the
dose is based on body weight and age (children 6 years
over weighing less than 75 kg receive 10 mg/kg, those
weighing 75 to 100 kg receive 750 mg, and those
weighing over 100 kg receive 1000 mg).
The same protocol as described above for patients
with RA was used in a multi-center double-blind
placebo-controlled study of 180 patients with SLE with
discoid rash, serositis, or polyarthritis. The results of the
study suggest some abatacept efficacy in patients with
non-life-threatening manifestations of SLE, but due to
safety issues, further assessment.is warranted [32].Efficacy
In a meta-analysis comparing phase II and III studies
including an extension phase, improvement in disease
activity in patients with RA, as measured by the ACR
score, was reported with combined therapy with abatacept
and DMARDs within 6 months. This included patients
who had not responded to prior anti-TNF-alpha therapy.
There was an average improvement of 50% in ACR20 in
the abatacept group, compared with 30% in the placebo
group. Similar results were found for ACR50 and ACR70
in the abatacept group compared with the placebo group
and with other treatment groups [33]. In a long-term
study comparing abatacept with placebo (with background
therapy for both groups of a steady dose of MTX), the
response to abatacept was superior and was maintained
for 3 years including physical function scores [34].
Evaluation of radiographic changes identified a reduc-
tion in bone erosion scores (Genant-modified Sharp
scoring method) every year within the 3-year follow-up,
and 40% of patients had no radiographic progression after
3 years [35].
In another study of 180 patients with SLE, abatacept
had a steroid-sparing effect and resulted in a lower rate
of flares. This effect was predominant in the lupus
patients with polyarthritis [32]. Furthermore, in the
abatacept group, significant improvement in well
being was reported by the HAQ (Health Assessment
Questionnaire) [32].Adverse effects and safety
The main AEs caused by abatacept are infections, URT
symptoms, nausea, headache, infusion reaction, fever,
hypertension, and back and limb pain.
In a study of long-term safety, 96% of patients experi-
enced AEs; however, most of them were mild to moder-
ate and mostly related to infections. No significant
differences in AEs were noted when the abatacept group
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Mechanism Golimumab (trade name Simponi) is a fully
human monoclonal IgG1 antibody, acting on both soluble
and membrane-bound TNF-α (Table 1) [36].
Indications and dosage Golimumab is approved by the
FDA for RA, psoriatic arthritis (PsA), and ankylosing
spondylitis (AS) (Table 1) [37-40]. The indicated dose
for all three diseases is 50 mg monthly by SC injection.
For RA, golimumab is administered in combination with
MTX; for PsA it may be administered alone or with
MTX; and for AS, it may be administered alone [40].
In a study comparing treatment groups given doses of
50 or 100 mg golimumab SC, no significant difference
occurred between the two groups. The lower dosage is
recommended by the FDA [37].
Efficacy In a study of patients with AS comparing
different doses of golimumab with placebo for 24 weeks,
a significant improvement was found in the AS Inter-
national Working Group criteria (20% improvement;
ASAS20) for all golimumab groups compared with the
placebo group [37]. In a similar study in patients with
PsA, using two different doses of golimumab; a significant
improvement was encountereed in both golimumab
groups compared with placebo [37]. Furthermore, there
was a significant improvement in both enthesitis and
Dactylitis Severity Score [37].
In a study of patients with RA who were not responsive
to MTX, (GO-FORWARD study [38]) the efficacy of
MTX plus placebo, MTX plus golimumab 50 mg, MTX
plus golilumab 100 mg, or golimumab 100 mg plus pla-
cebo, were compared. The most significant results were
seen in the MTX plus golimumab groups (both doses)
compared with MTX alone. However, a higher incidence
of AEs was noted in the golilumab 100 mg group [38]. In
another study (GO-BEFORE study [39]), using the same
protocol as the previous study but in MTX naïve patients
with RA, a significant response was seen with golimumab
as measured by ACR70, ACR90, 28-item Disease Activity
Score (DAS28), and HAQ [39]. The primary outcome of
ACR50 was not achieved, which could be attributable to
lower disease activity in these patients compared with
patients receiving other biologic therapy-based studies, as
well as to group size and possibly C-reactive protein
levels. However, the modified intention-to-treat analysis
of the primary endpoint and other pre-specified efficacy
measures did show efficacy in both the golimumab plus
MTX groups in these patients [39].Adverse effects and safety The main AEs are infections
(mostly of the URT) and nausea. Additional AEs include
hypertension, abnormal liver function (patients with latent
TB were required to take prophylactic treatment, resulting
in greater liver abnormalities), paresthesia, dizziness,
constipation, local skin reaction, and some cases of malig-
nancy (basal and squamous cell carcinomas, and prostate,
lung, and breast cancers) were reported [37-40].
In studies performed to assess golimumab safety, more
infections occurred in patients receiving golimumab
compared with those receiving placebo [36-39]. In the
study on patients with PsA, those who received 100 mg
golilumab had significantly higher rates of infections
than those who received 50 mg, but these were mainly
minor infections involving the URT [38].
Certolizumab pegol
Mechanism Certolizumab (trade name Cimzia) is a
pegylated Fab fragment of a humanized TNF-alpha mono-
clonal antibody, which binds to and inhibits TNF-alpha.
The pegylation extends the half-life of the antibody, and
the missing Fc fragment reduces the risk of cytotoxicity
(Table 1) [41,42].
Indications and dosage Certolizumab is approved by
the FDA for the treatment of active RA disease (Table 1),
given as SC injection of 400 mg every 2 weeks for three
consecutive cycles, followed by maintenance therapy of
200 mg SC every 2 weeks.
Efficacy In a study of patients diagnosed with RA for no
less than 6 months and no more than 15 years, who had
not received any biologic therapy for 6 months before
the beginning of the study, but had responded to anti-
TNF-alpha blockers in the past, were enrolled. The first
group was treated with MTX plus placebo and the second
with MTX plus certolizumab. ACR20 response, physical
improvement, and reduction in radiographic progression
were achieved more rapidly in the certolizumab group
compared with the placebo group over a 1-year period [41].
In a different study of patients with RA who had expe-
rienced treatment failure with DMARDs, a significant
ACR20 response of up to 50% was accomplished with
certolizumab monotherapy. Similar improvements were
also encountered for disease activity, physical function,
and arthritic pain [42].
Adverse effects and safety Other than the AEs already
recognized for treatment with TNF-alpha blockers, a
higher incidence of serious infections was noted with
certolizumab [42]; these AEs occurred with the lower
dose of 200 mg but not the higher dose of 400 mg [42].
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for certolizumab were headache, nasopharyngitis, diarrhea,
and sinusitis [42]. A significantly higher incidence of
serious AEs were detected in patients receiving
certolizumab, and these included bacterial arthritis,
salmonella arthritis, ischemic stroke, menorrhagia,
mastitis, and increases in blood creatinine and urea
levels [42]. There were no fatalities or cases of drug-
induced SLE [42].Sifalimumab
Sifalimumab is an anti-interferon (IFN)-alpha monoclonal
antibody. Patients with SLE carry a typical type I IFN sig-
nature. Compared with normal controls, overexpression
of B cell activation factor (BAFF) mRNA in whole blood
characterizes patients with SLE. The effect of anti-IFN
-alpha antibody was examined using B lymphocyte stimu-
lator/BAFF, and PCR identified suppression of BAFF
mRNA (Table 1) [43,44].
The safety of sifalimumab was evaluated in a phase I
trial of SLE. There were no drug-related AEs and no in-
crease in viral infections. In the trial, there was improve-
ment in disease activity with sifalimumab compared
with placebo [44], and the drug is currently in phase III
trials [20].Interleukin-1 inhibitors
Anakinra (trade name Kineret) is approved by the FDA
for treatment of RA. Recently, other IL-1 blockers became
available. Two of these are indicated for the treatment
of disorders collectively known as cryopyrin-associated
periodic syndromes (CAPS).
Canakinumab (trade name Ilaris) is specifically indicated
in adults and in children aged 4 years and older for
the treatment of CAPS, including familial cold auto-
inflammatory syndrome (FCAS) and Muckle-Wells
syndrome (MWS) (Table 1). For adults, it is administered
via SC injection at a dose of 150 mg every 8 weeks.
Canakinumab is beneficial, safe, and leads to a reduction
in serum amyloid A (SAA) and C-reactive protein (CRP)
levels. The associated AEs include infections [45].
Rilonacept (trade name Arcalyst) is an IL-1 blocker that
is also indicated for the treatment of CAPS, including
FCAS and MWS, in adults and in children aged 12 years
and older. Rilonacept (160 mg SC weekly for adults and
2.2 mg/kg or up to 160 mg for children) maintained
long-term efficacy and safety in an extension study of 72
to 96 weeks, including normalization of the inflammatory
markers CRP and SAA. AEs were mild to moderate, and
included injection site reactions and URTI [46]. IL-1
inhibitors are currently under investigation for the
treatment of acute gout flares [47].Intravenous immunoglobulin therapy
Mechanisms
IVIG is a well established therapy for immunodeficiency
diseases, and is beneficial for autoimmune diseases [48].
The immunoglobulins are derived from a pool of thou-
sands of healthy donors, containing antibodies to both
self and foreign antigens.
Several mechanisms of action are suggested for immu-
noglobulins, and they influence the immune system at
many levels. IVIG has a direct neutralization effect on
pathogenic antibodies, B and T cells, and macrophage
regulation. It inhibits the differentiation and maturation of
dendritic cells, prevents the presentation of self antigens,
modulates IL-1 receptor antagonists, and inhibits BLyS
activity (Table 1) [49].
Dosage protocols
The characteristics of the various IVIG products are not
discussed here, but can be readily found online (http://
www.medprorx.com/ref_ivig_drug.html). Different IVIG
protocols are in use, depending on the disease. In systemic
autoimmune diseases such as SLE, a high-dose proto-
col is often used, consisting of 2 g/kg divided over 5
days. This is repeated every 4 weeks, a period that allows
the immunoglobulin level in the serum to return to nor-
mal. The cycle repeats every month, usually for up to 6
months, and then every 2 to 3 months if required. Long
term, therapy remains beneficial [50]. To reduce AEs, a
single dose of hydrocortisone 100 to 200 mg should be ad-
ministered on day 1 before initiation of the IVIG ther-
apy. Treatment with a single dose of low-molecular
-weight (LMW) heparin before IVIG initiation may
prevent possible thromboembolic AEs [51]. Low-dose
IVIG therapy (400 mg/kg over 1 day every 3 to 4 weeks) is
beneficial for organ-specific disease, predominantly
neurological conditions [50]. It may also be useful for
some cases of mild to moderate SLE [52].
Efficacy
IVIG may be an adjunctive therapy for patients with SLE
who are refractory to conventional therapies. It may also
be an option for young women who do not wish to risk
the problems of disfigurement or sterility associated with
conventional immunosuppressive therapies. Based on
the various case reports and case series, it appears that
high-dose IVIG is beneficial for moderate to severe SLE.
It is beneficial for the treatment of serositis, cardiopulmo-
nary disease, hematological conditions, diffuse neuropsychi-
atric disease, and lupus nephritis [53-55]. In patients with
SLE, IVIG has a steroid-sparing effect [56]. High-dose
IVIG was beneficial for SLE, and led to a decrease in
various scores of disease activity. IVIG may be useful for
recalcitrant cases of organ-specific cutaneous LE including
discoid LE and subacute cutaneous LE. In many cases,
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low doses [48]. IVIG causes a serological improvement
including a decrease in antibody titer levels and an
increase in complement levels [49].
IVIG may be beneficial as off-label for a number of
other autoimmune diseases including Sjogren's syndrome,
polyneuropathy, severe PV, Still’s disease, and relapsing
anti-neutrophil cytoplasmic antibody-associated vascu-
litis [49]. Low-dose IVIG is beneficial for Guillain–Barré
syndrome, Lambert–Eaton syndrome, refractory myasthe-
nia gravis, refractory multiple sclerosis, multifocal motor
neuropathy, chronic inflammatory demyelination polyneur-
opathy, dermatomyositis, and stiff person syndrome [48].
In addition, polyneuropathy in SLE and vasculitis respond
well to IVIG therapy [57]. Other diseases in which IVIG is
used include refractory uveitis, Graves' disease, and ocular
involvement in Behcet's disease [48].
Adverse effects and safety
IVIG is usually associated with mild and transient AEs. The
common mild AEs include arthralgia, myalgia, weakness,
abdominal pain, diarrhea, chills, dizziness, drowsiness,
fatigue, fever, headache, and changes in blood pressure or
heart rate [50]. The more severe AEs include anaphylactic
reaction, thromboembolic events, neutropenia, pancyto-
penia, autoimmune hemolytic anemia, renal failure with
acute tubular necrosis, asthma exacerbation, hepatic
dysfunction, seizures, acute respiratory distress syndrome,
and aseptic meningitis [55,58]. AEs occurring with the
first course may return with further courses [50], and do
not usually worsen with long-term IVIG therapy [50].
Special attention is advised when treating patients with
pro-thrombotic risk and those with renal failure or who
are at risk of renal tubular injury (dehydration, renal
disease, diabetes). In cases where there is a high risk
of thromboembolic event, LMW heparin is to be ad-
ministered before initiation of the IVIG course. IVIG is
contraindicated in patients with IgA deficiency [49].
Immunogenicity of biologic therapies
Biologic agents are engineered molecular targeted ther-
apies, which include antibodies and receptor blockers.
Antibodies may be chimeric or fully human. As a result,
patients may develop immunogenicity to these agents,
characterized as development of antibodies to the biologic
agent itself, or the development of pathogenic autoanti-
bodies that can lead in some cases to the development of
another autoimmune disease. Antibodies targeted against
the biologic therapy, termed human anti-chimeric anti-
bodies (HACA), may lead to a decrease in the efficacy of
the medication, hence a DMARD (usually MTX) is
often recommended as co-treatment to counteract the
increased levels of HACA. With the availability of fully
human antibody biologic agents, the development ofHACA may be negligible. Although the development of
antinuclear antibodies and anti-double-stranded DNA
antibodies have been reported secondary to biologic
treatment, the development of frank SLE is infrequent.
However, drug-induced SLE secondary to biologic ther-
apies is not a mild disease, as usually seen for other medi-
cations, but rather a severe systemic disease with renal
impairment [59].
Immunogenicity of specific drugs
The newly developed drugs may not cause significant
immunogenicity effects. Several studies of TCZ showed
that the development of anti-chimeric antibodies had no
significant clinical effect [5].
In a study of 130 patients receiving ofatumumab, no
patients developed drug antibodies [25], and in a study of
belimumab treatment, negative seroconversion occurred
significantly more frequently in the belimumab treatment
group [27].
In a trial comparing the immunogenicity of epratuzumab
with rituximab, fewer anti-chimeric antibodies developed
compared to epratuzumab [29]. In a study of 339
patients receiving abatacept, only two patients developed
drug-related antibodies, which was not statistically signifi-
cant [32]. In the GO-FORWARD study of golimumab, only
2.1% of patients with RA developed drug antibodies [39].
In a phase I multi-center double-blind trial of 33 patients
treated with sifalimumab, there were no anti-sifalimumab
antibodies detected prior to administration or at several
points during the study [44]. In a study of 619 patients
treated with certolizumab, only 5.1% of patients devel-
oped anti-drug antibodies, which was not statistically
significant [42].
Discussion
We reviewed the literature on new biologic therapies
that have recently become available and how they are
used to treat various autoimmune diseases. Some of
these are new drugs in known classes (TNF alpha
blockers and B cell modulators),whereas others are of a
new class (BLyS inhibitors, IFN I inhibitors, IL-1 inhibi-
tors). The AEs are similar for all the biologic therapies
reviewed, with the severe AEs including serious infec-
tions. TB recurrence has been virtually eradicated due to
the accepted screening recommendations before starting
biologic therapy.
It is advantageous to have a range of effective biologic
drugs available for patients with severe or resistant
disease. Severe disease can include involvement of vital
systems, persistent disease despite conventional therapy
or even persistent and non-responsive disease despite
biologic therapies. Different drugs from the same class
(for example anti-TNF-alpha blockers) may provide further
treatment options. If a patient develops an AE from one
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TNF alpha blocker or to another class of drugs (for
example, B-cell modulators). Furthermore, if there was
an initial efficacy response that ceased over time, a switch
to a different biologic class may achieve a favorable result.
With the various available biologic therapies, the therapy
can be tailored to the individual patient. For example, IV
therapy may be suitable for patients who need medical
supervision, whereas SC therapy may be suitable for
patients who feel confident injecting the drug in the
privacy of their own home. In addition, the choice of
biologic may be customized to include considerations of
co-morbidities or the need for concomitant drug treatment.
There is a focus on early treatment, yet none of the biologic
therapies is yet available as first-line medication for auto-
immune diseases, probably due to economic concerns. Be-
cause the complexity of preparing biologic drugs has
diminished over the years, costs may be driven down,
allowing biologic therapies to be used at an early stage of
disease and hence enable prevention of irreversible damage.
Conclusions
The arsenal of biologic therapies available to treat auto-
immune diseases is quickly expanding as a result of better
understanding of molecular mechanisms together with im-
proved production capacity. They include (by class): novel
anti-TNF alpha blockers (fully humanized or pegylated),
anti-IL agents (to IL-1, IL-6), B-cell-directed therapies (to
CD20, CD22), co-activation signaling (CTLA4-Ig), and
IVIG. Although most of the FDA-approved biologic ther-
apies are for RA, Belimumab is the first FDA-approved
targeted therapy for SLE. In addition, the efficacy and
safety for biologics in off-label indications are encouraging
for patients with resistant autoimmune conditions.
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